vaccination candidate Articles
-
MSD Wellcome Trust Hilleman Laboratories, India - Case Study
“With the spray drying technology, we have been able to achieve positive outcomes on our flagship vaccine candidate and are planning to extend the technology to other antigens and biopharmaceuticals as well.” Customer name Dr. Nitin Saigal, Formulation Scientist Company / Institution MSD Wellcome Trust Hilleman Laboratories, India Product lines Spray Drying and Encapsulation ...
By BUCHI
-
Research And Development of Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development. ...
-
HIV-1 subtype C vaccine: waiting in wings for the human trials
India has more than 5 million people infected with HIV-1 and this number is likely to increase in coming years. It is estimated that by the turn of this decade more than 10 million people would have been infected with this virus. More than 90% of these infections are due to subtype C. Therefore, it is imperative that a vaccine be developed based on local circulating subtype and tested for ...
-
Rational Vaccines Announces a Clinical Trial to Determine Baseline Characteristics of Patients Diagnosed With Recurrent Symptomatic Herpes Simplex Type 2 (HSV-2) Virus
Study to be conducted at two leading research institutions in the U.K. Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the ...
-
Rational`s Experimental Herpes Vaccine Shows Preclinical Promise
Rational Vaccines said findings from a pilot study showed that RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine in animal studies. Rational's Experimental Herpes Vaccine Shows Preclinical Promise Rational Vaccines said findings from a pilot study showed that RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine ...
-
Vaccine Projects
Abera’s vaccine delivery platform works as a plug-and-play system where known or novel antigens can be engineered onto our delivery platform to create effective, multivalent vaccines that are cost-effective and fast to produce. We actively work together with academia and industry to enable the use of our vaccine delivery platform in design and development of new vaccines. Many of these ...
-
RVx201 Herpes Vaccine
RVx201 Herpes Vaccine Description 2022 RVx201 is a first-in-human herpes simplex virus type 2 (HSV-2) live-attenuated therapeutic vaccine modified to be interferon sensitive that destroys the ability of the virus to inhibit immune responses. Produced by Rational Vaccines, Inc., the technology is based on the pioneering research of the late Dr. William Halford, who dedicated over 25 years to ...
-
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal ...
By FluGen, Inc.
-
Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection
LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate Tailored to Individuals’ Genetics ...
-
Nipah virus glycoprotein structure suggests therapeutic strategies
Recent molecular discoveries have provided new details on how Nipah and Hendra viruses attack cells, and the immune responses that fight back against this attack. The findings point to a multi-pronged strategy for preventing and treating these deadly diseases. The study was published in Science recently. Both Nipah virus and Hendra virus are carried by indigenous bats in some parts of the ...
-
Bioprocess Automation, Remote Monitoring, and Real-Time Data Capture Underpin Operation Warp Speed’s Push for a COVID-19 Vaccine
Life science companies spanning the globe are striving to quickly develop and commercialize COVID-19 therapeutics and grab the brass ring of a viable, effective, and safe SARS-CoV-2 vaccine. In the United States, pharmaceutical and biotech companies, as well as Contract Development and Manufacturing Organizations (CDMOs), from coast-to-coast are racing to complete clinical trials and forge ...
By Lab Owl
-
FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus
Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain – MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of results from its Phase 2 human challenge ...
By FluGen, Inc.
-
FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine
Study is the Company’s first trial evaluating ability of M2SR and the current licensed standard of care to protect against drifted virus strains, and its second study in older adults, a population most vulnerable to mortality from flu – Safety and immunogenicity study expected to begin in Q2 2022 – MADISON, Wis., July 1, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage ...
By FluGen, Inc.
-
Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection
The cornea is essential for vision yet highly sensitive to immune-mediated damage following infection. Generating vaccines that provide sterile immunity against ocular surface pathogens without evoking vision loss is therefore clinically challenging. Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause ...
-
The race to a vaccine - unintended consequences?
A gold rush is on to find a vaccine for COVID-19. According to the World Health Association (WHO) in early May, there are more than 100 projects around the world centered on the development of a vaccine for the coronavirus. Eight candidate vaccines are already being tested in people in clinical trials. Once an effective vaccine (or vaccines) has been identified, it will need to be produced ...
By Vistex Inc
-
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
MADISON, Wis.–(BUSINESS WIRE)–An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this CoroFlu will build on the ...
By FluGen, Inc.
-
Micron developing microneedle technology for self-administration of vaccines and therapeutics
Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics. “While microneedle technology is not new, our company represents the evolution of the technology over many years,” Steven Damon, CEO, says in an interview with BioTuesdays.com. “We’re developing an innovative ...
-
Adventitious viruses in insect cell lines used for recombinant protein expression
Abstract Insect cells are widely used for recombinant protein expression, typically as hosts for recombinant baculovirus vectors, but also for plasmid-mediated transient transfection or stable genetic transformation. Insect cells are used to express proteins for research, as well as to manufacture biologicals for human and veterinary medicine. Recently, several insect cell lines used for ...
-
Characterization of an Sf-rhabdovirus-negative Spodoptera frugiperda cell line as an alternative host for recombinant protein production in the baculovirus-insect cell system
Abstract Cell lines derived from the fall armyworm, Spodoptera frugiperda (Sf), are widely used as hosts for recombinant protein production in the baculovirus-insect cell system (BICS). However, it was recently discovered that these cell lines are contaminated with a virus, now known as Sf-rhabdovirus [1]. The detection of this adventitious agent raised a potential safety issue that could ...
-
A Brown pathology professor may have developed a revolutionary new approach to battling one of the world’s deadliest diseases
Jonathan “Jake” Kurtis was riding a night train from Nairobi to Mombasa when he first began to feel sick. Then a 20-year-old Brown junior, Kurtis had gone to the restaurant car for a curry and stayed up late drinking beer with some Americans he’d met. By the time he got back to his sleeper car, he had a vicious headache. “I thought God had visited upon me a righteous ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you